The kallikrein-kinin system in diabetic nephropathy - Wikidata - awgldk - TriplyDB

The kallikrein-kinin system in diabetic nephropathy

The kallikrein-kinin system in diabetic nephropathy

http://www.wikidata.org/entity/Q26827473

about

Autoimmune diabetes is suppressed by treatment with recombinant human tissue Kallikrein-1 Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus Administration of angiotensin II and a bradykinin B2 receptor blocker in midpregnancy impairs gestational outcome in guinea pigs.Plasma bradykinin and early diabetic nephropathy lesions in type 1 diabetes mellitus Classical Renin-Angiotensin system in kidney physiology Kinin B2 receptor does not exert renoprotective effects on mice with glycerol-induced rhabdomyolysis.Poor histological lesions in IgA nephropathy may be reflected in blood and urine peptide profiling.Local bone interaction between renin-angiotensin system and kallikrein-kinin system in diabetic rat.Early urinary biomarkers of diabetic nephropathy in type 1 diabetes mellitus show involvement of kallikrein-kinin system.Plasma metabolomic profiles in association with type 2 diabetes risk and prevalence in Chinese adults.Nitric oxide in the normal kidney and in patients with diabetic nephropathy.Kinin B1 Receptor Deletion Affects Bone Healing in Type 1 Diabetic Mice.Implication of the Kallikrein-Kinin system in neurological disorders: Quest for potential biomarkers and mechanisms.Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney Disease.The Gut-Kidney Axis: Putative Interconnections Between Gastrointestinal and Renal Disorders

P2860

Q27348019-298E8F47-BAE9-4C8C-B1DC-06EEFEC00A29 Q28541677-EE88E91D-212A-4E7A-9D68-AB46642B6AC7 Q33774507-8E2D9100-AC11-4437-A22F-FEA93C4EBE82 Q33897901-7F9AFB3B-9B6F-45D0-B56D-A7655032B905 Q34065655-13F15DF0-925A-4FBE-9240-A0F11A0D526F Q34367677-46E849CE-C31E-423B-8DA6-A1C07B86739F Q34664488-EACB5E14-7D09-4F20-A95E-96958E25366D Q35406226-0F1262FA-CE6D-4338-BD9A-2B8BA35CA5EA Q36328641-1437F417-2DF3-43F9-8AD2-3D3FB0C2010D Q37403973-65079B30-BB85-45CC-A210-5841B08CED11 Q38248725-A42BEC2D-677E-4EBA-8DB1-E1DCD4D101C8 Q40944950-8BD949DC-97E3-4C73-B048-625F6940618C Q47720411-AE460A49-55E0-4DBC-A55A-1471711F06D5 Q52630076-41D506A6-0E3D-40ED-8D5F-22F48C09C1C1 Q57072601-6D2F2D94-E33A-4E33-AD43-37D89DBBCB08

P2860

The kallikrein-kinin system in diabetic nephropathy

http://www.wikidata.org/entity/Q26827473

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The kallikrein-kinin system in diabetic nephropathy

@ast

The kallikrein-kinin system in diabetic nephropathy

@en

The kallikrein-kinin system in diabetic nephropathy

@nl

type

label

The kallikrein-kinin system in diabetic nephropathy

@ast

The kallikrein-kinin system in diabetic nephropathy

@en

The kallikrein-kinin system in diabetic nephropathy

@nl

prefLabel

The kallikrein-kinin system in diabetic nephropathy

@ast

The kallikrein-kinin system in diabetic nephropathy

@en

The kallikrein-kinin system in diabetic nephropathy

@nl

P1433

Q26827473-C361EC31-0FA7-49F1-B9E1-F0DEA04AF8CC

P1476

Q26827473-38998C01-F5A1-4C1F-AE02-D568BFEDADA1

P2093

Q26827473-5559C745-9C3E-4B38-AC33-23A84714D6F0

Q26827473-86EAC6AE-078C-4570-A7AA-149D4B7FB56B

Q26827473-C1F02832-8892-4C47-A8C2-EB69D6981D65

P2860

Q26827473-00B26868-65BF-4B94-BC3E-C8BA4292D189

Q26827473-04AB64F3-3746-4941-9E58-4F8B68482BEF

Q26827473-06AD78D1-CDC9-45D7-B97C-391CD7F9D542

Q26827473-0A75D685-736D-4F96-9559-C78ED461BB0F

Q26827473-0B0B901A-DEFC-43D1-B324-CB00F7879C88

Q26827473-0C6EAC8C-8D86-4EFC-B354-FFAB0493BCAB

Q26827473-0D7A2D87-B7E4-44C6-922D-3ECE7C2D1850

Q26827473-1288865A-58B8-4168-AC28-B6183AE06559

Q26827473-18F0A589-6D1C-4A0E-AE62-15D9EC323617

Q26827473-1A3DECD0-D8F2-4984-8D67-71B2A76621D9

P2888

Q26827473-E04F7BF6-0022-4B98-A5EA-18CD20CEA99E

P304

Q26827473-8B567A78-D04B-4099-84A8-46E5EB897CA0

P31

Q26827473-7411BD20-3CBD-46E9-B63B-BFBEEE89A197

Q26827473-895FC5A8-4D8B-4066-B9DF-B774352617B7

P356

Q26827473-3EA85776-98B1-4BE1-902D-08740087A5DD

P407

Q26827473-181CD176-9078-4B8B-A4E0-61D7430C6AC6

P433

Q26827473-43A9D33C-994D-4B99-8AA3-7D9634B8BB97

P478

Q26827473-BFA3BE38-8478-44CD-B09B-1DBFEB50B3BC

P50

Q26827473-29DA3501-54D4-4E37-BAD9-7ED809B73DBF

P577

Q26827473-0D09F777-86E8-4460-8892-E6E46689C1BB

Q26827473-A8A15DE5-5D79-4539-8430-B0BBEE53B4B4

P5875

Q26827473-6D060C63-CD43-43A8-A60A-4D2C4F7DE203

P6179

Q26827473-37FF42D0-13EA-444B-A3B0-2C6D97260D30

P698

Q26827473-A86C2644-53B6-4F9F-A423-C5CC56CC6EA5

P921

Q26827473-F0F8EA91-803F-42FF-8E37-039F8AA8C9D0

P932

Q26827473-D72E7C8A-2979-4DEF-919E-CC886AA83D95

P356

P1433

Kidney International

P1476

The kallikrein-kinin system in diabetic nephropathy

@en

P2093

Hirofumi Tomita

http://www.w3.org/2001/XMLSchema#string

Masao Kakoki

http://www.w3.org/2001/XMLSchema#string

Ryan B. Sanford

http://www.w3.org/2001/XMLSchema#string

P2860

cAMP controls oxygen metabolism in mammalian cells

Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase

Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides

Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries

Nitric oxide: physiology, pathophysiology, and pharmacology

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences

A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation

Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

P2888

P304

733-44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2011.499

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

81

http://www.w3.org/2001/XMLSchema#string

P50

Oliver Smithies

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221817371

http://www.w3.org/2001/XMLSchema#string

P6179

1041215784

http://www.w3.org/2001/XMLSchema#string

P698

22318421

http://www.w3.org/2001/XMLSchema#string

P921

physiological phenomena

P932

3498986

http://www.w3.org/2001/XMLSchema#string